Even though we demonstrated that gene suppression of SOD1 in glioma cells has significant effects on cell survival, further in vivo animal studies and clinical trials on the efficacy and safety of ATN-224 monotherapy and combinational therapy with e.g. irradiation or mTORC1 inhibitors are exciting future options for a SOD1-targeted therapeutic approach to GBs. This evidence concerns the gene SOD1 and Guillain-Barre syndrome.